Polly Niravath

2.2k citations

53 papers · 970 indexed · h-index 14

Family Practice top 5%
Oncology top 5%
- HER2/EGFR in Cancer Research 14
- Cancer Treatment and Pharmacology 14
- Cancer Risks and Factors 4
Cancer Research top 10%
- Breast Cancer Treatment Studies 12
Urology top 5%
Dermatology top 5%
Pulmonary and Respiratory Medicine
- Advanced Breast Cancer Therapies 17
- Brain Metastases and Treatment 6
Genetics
- Estrogen and related hormone effects 7
- Chronic Lymphocytic Leukemia Research 3

Co-authors: Swapan Dasgupta Rolando E. Rumbaut Shigekazu Nagata Anhquyen Le Hanan Abdel‐Monem Perumal Thiagarajan Mothaffar F. Rimawi Susan G. Hilsenbeck
Cited by: Family Practice Oncology Cancer Research
Journals: Journal of Clinical Oncology (9 papers)Advances in Therapy (6 papers)Cancer Research (5 papers)
Partner nations: United States Canada Japan

In The Last Decade

Polly Niravath

49 papers receiving 950 citations

Peers

Countries citing papers authored by Polly Niravath

Since Specialization

Citations

This map shows the geographic impact of Polly Niravath's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Polly Niravath with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Polly Niravath more than expected).

Fields of papers citing papers by Polly Niravath

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Polly Niravath. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Polly Niravath. The network helps show where Polly Niravath may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Polly Niravath, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Polly Niravath Line = papers co-authored together Polly Niravath links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Abstract PO5-12-09: A Single-Arm Pilot Study of the Feasibility and Efficacy of Electro-Acupuncture in Subjects with Chemotherapy-Induced Peripheral Neuropathy Cancer Research ·Seniha Hasipek,Κωνσταντίνος Σαββόπουλος,Shaikh K.,Dharamvir Jain,Catty Castillo-Caicedo,典礼太田,Jenny C. Chang,Sudhir Krishnamurthi,Tejal Patel,Polly Niravath	2024	0
2	Characterization of the Breast Cancer Liver Metastasis Microenvironment via Machine Learning Analysis of the Primary Tumor Microenvironment Cancer Research Communications ·Simmons,Eric Chau,Winnie Furnari,X. Q. Ai,Anjana Tiwari,Yitian Xu,Polly Niravath,Shu‐Hsia Chen,Biana Godin,Hermann B. Frieboes	2024	2
3	Clinical factors and association with treatment modalities in patients with breast cancer and brain metastases who develop leptomeningeal metastases Breast Cancer Research and Treatment ·何艳芬,Rujukan Upp,Siti Fatimatuzzahra Binti Roseli,Tejal Patel,Bin S. Teh,Ivo W. Tremont‐Lukats,Jenny C. Chang,Polly Niravath	2022	3
4	Anti-Yo-Associated Paraneoplastic Cerebellar Degeneration: Case Series and Review of Literature Cureus ·Aziza Abozid,Polly Niravath	2021	6
5	The impact of HER2-directed targeted therapy on HER2-positive DCIS of the breast Reports of Practical Oncology & Radiotherapy ·Gary D. Lewis,Waqar Haque,Andrew Farach,Sandra S. Hatch,E. Brian Butler,Polly Niravath,Mary R. Schwartz,Elizabeth Bonefas,Bin S. Teh	2021	4
6	Pulmonary arterial hypertension in breast cancer patients on HER2-targeted therapy: a review of FDA Adverse Events Reporting System data ERJ Open Research ·Valentine L. MIKHEICHEVA,S. B. IMOSSEIR,Guangxin Tan,Polly Niravath,Sandeep Sahay	2020	6
7	TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer Clinical Cancer Research ·Mothaffar F. Rimawi,Polly Niravath,Tao Wang,Brent N. Rexer,Andres Forero,Antonio C. Wolff,Rita Nanda,Anna Maria Storniolo,Ian E. Krop,Matthew P. Goetz,Julie R. Nangia,Sao Jiralerspong,Anne C. Pavlick,Jamunarani Veeraraghavan,Carmine De Angelis,Carolina Gutiérrez,Rachel Schiff,Susan G. Hilsenbeck,C. Kent Osborne	2019	34
8	Comparison of outcomes between metaplastic and triple-negative breast cancer patients The Breast ·Ausonius Decimus Magnus Ausonius,Waqar Haque,สิริวิท อิสโร,Vivek Verma,Mary R. Schwartz,V. Suzanne Klimberg,Sandra S. Hatch,Polly Niravath,E. Brian Butler,Bin S. Teh	2019	29
9	Economic Burden of HR+/HER2- Metastatic Breast Cancer Among Adult Premenopausal Women Advances in Therapy ·Geneviève Gauthier,Patrick Gagnon‐Sanschagrin,Annie Guérin,Rebecca Burne,Artur Paes Chagas,Polly Niravath,Anand A. Dalal	2018	9
10	Monitoring of Hematologic, Cardiac, and Hepatic Function in Post-Menopausal Women with HR+/HER2− Metastatic Breast Cancer Advances in Therapy ·Annie Guérin,良一立林,Artur Paes Chagas,Patrick Gagnon‐Sanschagrin,歌子菊地,Geneviève Gauthier,Sneha S. Kelkar,Eric Q. Wu,Polly Niravath,Anand A. Dalal	2018	1
11	Current Treatment Patterns Among Postmenopausal Women with HR+/HER2− Metastatic Breast Cancer in US Community Oncology Practices: An Observational Study Advances in Therapy ·Deborah Goldschmidt,Anand A. Dalal,歌子菊地,Sneha S. Kelkar,Annie Guérin,Geneviève Gauthier,Eric Q. Wu,Polly Niravath,Artur Paes Chagas	2018	9
12	Progression-free Survival With First-line Endocrine-based Therapies Among Postmenopausal Women With HR+/HER2– Metastatic Breast Cancer: Clinical Therapeutics ·Rajeev Ayyagari,Derek Tang,Oscar Patterson‐Lomba,Zhou Zhou,Jipan Xie,David Chandiwana,Anand A. Dalal,Polly Niravath	2018	9
13	Interventions to improve endocrine therapy adherence in breast cancer survivors: what is the evidence? Journal of Cancer Survivorship ·Jongkeyong Kim,A.P. Zhang,Geoffrey H. Hancock,Aisha Vadhariya,Reina Silva G,Polly Niravath,Susan Abughosh,Meghana V. Trivedi	2018	50
14	Vitamin D Levels, Vitamin D Receptor Polymorphisms, and Inflammatory Cytokines in Aromatase Inhibitor-Induced Arthralgias: An Analysis of CCTG MA.27 Clinical Breast Cancer ·Polly Niravath,Bingshu E. Chen,Judy-Anne W. Chapman,Sandeep K. Agarwal,Е. Д. Кущ,Tim Bongartz,Krishna R. Kalari,Lois E. Shepherd,John M.S. Bartlett,Kathleen I. Pritchard,Karen A. Gelmon,Susan G. Hilsenbeck,Mothaffar F. Rimawi,C. Kent Osborne,Paul E. Goss,James N. Ingle	2017	19
15	Unique Breast Cancer Features Within the Vietnamese Population Digital Scholarship - UNLV (University of Nevada Reno) ·Polly Niravath,Melissa L. Bondy,Susan G. Hilsenbeck	2016	0
16	Prognostic Factors, Treatment, and Outcomes in Early Stage, Invasive Papillary Breast Cancer American Journal of Clinical Oncology ·Brezany,Waqar Haque,Awad A. Ahmed,Mary R. Schwartz,Andrew Farach,Arnold C. Paulino,Elizabeth Bonefas,Darlene M. Miltenburg,Polly Niravath,E. Brian Butler,Bin S. Teh	2016	7
17	Vaginal estrogen products in hormone receptor-positive breast cancer patients on aromatase inhibitor therapy Breast Cancer Research and Treatment ·睦山口,Elaine Cristina Cicero,Weiqun Wang,Raksha R. Bhat,Meghana V. Trivedi,Polly Niravath	2016	21
18	The risk of febrile neutropenia and need for G-CSF primary prophylaxis with the docetaxel and cyclophosphamide regimen in early-stage breast cancer patients: a meta-analysis Breast Cancer Research and Treatment ·務田代,Akshay Ashok Kshirsagar,Raksha R. Bhat,Hua Chen,Polly Niravath,Meghana V. Trivedi	2015	20
19	Breast adenocarcinoma recurring as small cell carcinoma in a patient with a germline BRCA2 mutation: clonal evolution unchecked Experimental Hematology and Oncology ·Polly Niravath,Tanya N. Eble,Alejandro Contreras,Marilyn M. Li,Luis M. Franco,Mothaffar F. Rimawi	2015	3
20	Utility of screening for hepatocellular carcinoma among cirrhotics Frontline Gastroenterology ·Polly Niravath,Teresa G. Hayes,Susan G. Hilsenbeck	2011	2

About Polly Niravath

Polly Niravath is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Family Practice and Genetics, having authored 53 papers that have together received 970 indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (17 papers), HER2/EGFR in Cancer Research (14 papers), Cancer Treatment and Pharmacology (14 papers), Breast Cancer Treatment Studies (12 papers), Estrogen and related hormone effects (7 papers), Brain Metastases and Treatment (6 papers), Cancer Risks and Factors (4 papers) and Chronic Lymphocytic Leukemia Research (3 papers). The work is most often cited by research in Family Practice (44 citations), Oncology (456 citations), Cancer Research (227 citations), Urology (90 citations) and Dermatology (120 citations). Polly Niravath has collaborated with scholars based in United States, Canada and Japan. Frequent co-authors include Swapan Dasgupta, Rolando E. Rumbaut, Shigekazu Nagata, Anhquyen Le, Hanan Abdel‐Monem, Perumal Thiagarajan, Mothaffar F. Rimawi, Susan G. Hilsenbeck, Meghana V. Trivedi and Tao Wang. Their work appears in journals such as Journal of Clinical Oncology, Advances in Therapy, Cancer Research, Breast Cancer Research and Treatment and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact